Indeed, although platinum-based therapies are not the standard of care for breast cancer, they can have utility in carriers of pathogenic mutations in BRCA1 and BRCA2 genes, who are particularly sensitive to platinum-based drugs [11]. This evidence concerns the gene BRCA1 and breast cancer.